Femasys Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Femasys Inc. (NASDAQ: FEMY) announced that CEO Kathy Lee-Sepsick will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The presentation will be available on-demand starting at 7:00 AM ET on September 12.
The conference will feature a fireside chat format, and Femasys management will hold one-on-one meetings during the event. Femasys focuses on developing minimally invasive technologies for reproductive health, including FemBloc® for birth control and FemaSeed® for infertility.
- None.
- None.
Insights
Analyzing...
ATLANTA, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Kathy Lee-Sepsick, founder, president & chief executive officer, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference being held on a hybrid basis September 12-14, 2022, and in-person at the Lotte New York Palace Hotel in New York, NY.
H.C. Wainwright 24th Annual Global Investment Conference
| Date: | Monday, September 12, 2022 |
| Format: | Fireside chat |
| Time: | Available on-demand starting at 7:00 AM ET |
The Femasys management team will also participate in one-on-one meetings during the event. Interested investors should contact their H.C. Wainwright representative.
About Femasys
Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc® permanent birth control and FemaSeed® localized directional insemination for infertility. The Company’s product for fallopian tube assessment by ultrasound, FemVue®, is currently marketed in the United States. Femasys is also advancing FemCath™, an intrauterine catheter for selective evaluation of the fallopian tubes and FemCerv®, an endocervical tissue sampler that is the first product of the technology platform for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting. To learn more, visit www.femasys.com or follow us on Twitter and LinkedIn.
Contacts:
Investors
Chuck Padala
LifeSci Advisors, LLC
+1-917-741-7792
chuck@lifesciadvisors.com
Media
Karissa Cross, Ph.D.
LifeSci Communications
kcross@lifescicomms.com
Femasys Inc.
Investor Contact:
IR@femasys.com
Media Contact:
Media@femasys.com
FAQ
What is the date of Femasys' presentation at the H.C. Wainwright conference?
What is the format of Femasys' presentation at the conference?
Who is presenting on behalf of Femasys at the conference?
What are Femasys' key products mentioned in the press release?
How can investors schedule one-on-one meetings with Femasys during the conference?
